China NMPA Drug Inspection - Guangdong Wanfang Pharmaceutical Co., Ltd. - Lily Gold Tablets

China NMPA drug inspection for Guangdong Wanfang Pharmaceutical Co., Ltd. published June 17, 2021. Drug: Lily Gold Tablets.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

China NMPA drug inspection for Guangdong Wanfang Pharmaceutical Co., Ltd. published June 17, 2021. Drug: Lily Gold Tablets.

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Guangdong Wanfang Pharmaceutical Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: b2518094-2f14-44c8-b028-43a1f9a19c42

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox